Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.

NCT01682876 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01682876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01682876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
October 7, 2012
Completion date
May 30, 2014
Enrollment
715 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal, meningococcal disease